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Abstract
Given the limited lifespan and with the recent progress in experimental treatments for 
WS, timely diagnosis and multidisciplinary treatment for DI/DM, hydronephrosis, 
and visual/psychiatric status—maintaining quality of life—are of crucial importance.
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1 |  INTRODUCTION
WS is a rare neurodegenerative disorder. Two sisters, a 19‐
yr blind since 13 (died at 21, due to brain stem atrophy) 
and a 7‐yr‐old, from nonconsanguineous parents originated 
from Trapezund, had poorly treated DM since 3  years and 
untreated DI. Genetic testing revealed a novel homozygous 
c.2069G > A mutation in WFS1.
Wolfram syndrome (WS), also called DIDMOAD (diabe-
tes insipidus, diabetes mellitus, optic atrophy, and deafness), 
is a rare autosomal recessive neurodegenerative genetic dis-
order.1 The prevalence of WS has been estimated between 1 
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in 770 000 in the United Kingdom and 1 in 100 000 in North 
America.2 Two causative genes have been identified: WFS1 
and CISD2 (WFS2).3 Classical WS is the result of autosomal 
recessive mutations affecting the WFS1 gene, which is im-
plicated in endoplasmic reticulum (ER) function,2 although 
WS was first described as a mitochondriopathy. However, the 
localization of the protein on the endoplasmic reticulum (ER) 
membrane challenged this hypothesis. ER contacts mito-
chondria to ensure effective Ca++ transfer and lipids transfer, 
and apoptosis within stabilized and functionalized micro-
domains, termed “mitochondria‐associated ER membranes” 
(MAMs).4 The prognosis of the syndrome is currently poor. 
The median age at death is 30 years (range, 25‐49 years), usu-
ally from respiratory failure as a result of brain stem atrophy.5
2 |  CASE REPORT
Two sisters from nonconsanguineous parents presented to 
our pediatric endocrinology clinic due to severe polyuria‐
polydipsia. They both had poorly treated diabetes mellitus 
since the age of 3 years and untreated diabetes insipidus (DI).
A 19‐yr‐old girl totally blind since the age of 13 had pri-
mary amenorrhea and bladder incontinence. Cranial nerve 
examination was normal except oculomotion with roving eye 
movements. Muscle strength was normal with deep tendon re-
flexes 2/4. There were no signs of ataxia nor extrapyramidal 
signs. Mental status was appropriate for age but suffered from 
insomnia and apparent depression. Her HbA1c was 8.2%, bio-
chemical values being normal. Gonadotropins in GnRH test-
ing as well as estradiol levels and thyroid function tests were 
normal. Abdominal ultrasonography revealed normal uterus 
and ovaries but inappropriate for pubertal stage along with 
mild (Grade II) hydronephrosis. Comprehensive ophthalmic 
examination showed “No Light Perception” in both eyes. The 
pupillary light reflex was completely absent, and both pupils 
were mid‐dilated. The anterior segment was normal, and the 
intraocular pressure was 12  mm  Hg in both eyes (Goldman 
application tonometer). Dilated fundus examination revealed 
complete optic nerve atrophy. Otologic and audiologic evalua-
tion was performed. They included otomicroscopy, tympanom-
etry, transient otoacoustic emissions (TOAE), and automated 
auditory brainstem response (aABR). Her tympanogram was 
type A, TOAEs “pass” bilateral, as well as aABRs.
The patient had severe salt‐wasting diuresis when treatment 
for diabetes insipidus was started,6 and fludrocortisone was 
necessary to be added, along with frequent bladder catheteriza-
tions for her neurogenic bladder. Six months after appropriate 
treatment for diabetes mellitus and insipidus, she had menstrual 
onset. Unfortunately, 2 years after presentation, she died unex-
pectedly in her sleep. Autopsy showed severe brain stem atrophy.
Her 7‐year‐old sister had normal neurological examina-
tion. She was prepubertal. Her HbA1c was 10.1%, the rest 
biochemical values being normal. Abdominal ultrasonog-
raphy revealed mild to severe hydronephrosis (Grade III). 
Ophthalmic examination showed a visual acuity 6/15 (0.40 
LogMAR) in her right eye and 6/19 (0.50 LogMAR) in her 
left eye with + 1.00 diopters sphere corrective lens in both 
eyes. The pupillary light reflex was reduced symmetrically in 
both eyes, but there was not relative afferent pupillary reflex. 
The anterior segment was normal, and the intraocular pres-
sure was 12 mm Hg in the right and 11 mm Hg in the left 
eye (Goldman application tonometer). Dilated fundus exam-
ination revealed moderate optic nerve atrophy. Otologic and 
audiologic tests revealed a type C tympanogram, right side 
“pass” and left “fail” of TOAEs, whereas aABRs were “pass” 
bilateral.
She also presented severe salt‐wasting diuresis when 
treatment for diabetes insipidus was started, and fludrocorti-
sone was necessary to be added for 1 month only, along with 
frequent urinary catheterizations for her neurogenic bladder. 
On the contrary, we were not able to discontinue fludrocorti-
sone in her sister.
They both normalized their HbA1c (<7%) under intensi-
fied multiple insulin daily injections with the 24‐hr analogue 
degludec (Tresiba®) and the newest faster formulation of as-
part (Fiasp®). Glucose variability was also optimized using 
the FlashStyle Libre System, minimizing hypoglycemia and 
confining postprandial hyperglycemic excursions. Adjunctive 
treatment with idebenone 600 mg × 3 p.o. was given to the 
younger sister aiming to visual stabilization7—proven suc-
cessful for 2.5  years now—while both sisters received ad-
ditional pioglitazone therapy 45  mg/d  ×  1 p.o. aiming to 
mitigate β‐cell death.8
Genetic testing was performed to confirm the clinical di-
agnosis of WS. DNA was tested with PCR amplification and 
sequencing analysis (Sanger sequencing) of the entire coding 
region and all exon‐intron splice junctions of the WFS1 gene 
(chromosome 4): reference sequence: NM_006005.3, with 
the A of the ATG start codon at position 1. A homozygous 
c.2069G > A mutation in WFS1 gene was found in both sis-
ters, whereas the parents were carriers. This point mutation 
is a missense mutation in amino acid position 690 (p.C690Y) 
replacing cysteine with tyrosine in exon 8. To our knowledge, 
this is a novel variant in WFS1 gene, not previously reported 
in patients with WS. According to the Prediction Program 
PolyPhen‐2, the mutation is predicted to be damaging with a 
score of 1000. A different heterozygous—not related to dis-
ease manifestation—missense mutation at the same codon 
has been reported (690Cys‐ > Arg).
3 |  DISCUSSION
We have previously reported a novel homozygous WFS1 gene 
mutation due to maternal uniparental disomy of chromosome 
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4.9 Now we present a novel detrimental homozygous WFS1 
gene mutation, adding to the genotype‐phenotype correlation 
reported so far.10 The two sisters affected were born from 
nonconsanguineous parents of Greek descent born in dis-
tant regions of Russia. However, detailed genealogical his-
tory proved that both originated 5‐6 generations before from 
Trapezund, an ancient Greek colony located in the Greek—
until 1922—Pontus, presently in the state of Turkey, indicat-
ing a founder mutation effect.
Even though a correct diagnosis of WS had been made 
several years ago, none of the girls had ever received treat-
ment for DI. Their diabetes was poorly controlled, and their 
quality of life was poor. No care had been ever provided for 
their hydronephrosis nor their psychiatric status. Given the 
known effect of glycemic control on the neurodegenerative 
process 10 and the severe consequences of untreated DI such 
as failure to thrive and hydronephrosis, proper treatment 
of endocrine dysfunctions is crucial not just to avoid con-
sequences but also to improve quality of survival.11 In our 
center, proper multidisciplinary care along with adjunctive 
treatment with idebenone 7 and pioglitazone 8,12 has resulted 
in stabilization of visual status, resume in growth and pu-
bertal development, normalization of BMI and improved 
quality of life in our previously reported patient 9 as well 
as the younger of the two sisters currently reported. The 
fact that the life span in WS is limited but progress in ex-
perimental treatments—that hopefully will be soon widely 
available—has been made 13 underlines the importance of 
timely diagnosis and effective multidisciplinary approach in 
centers with experience in complex endocrine pathologies 
such as WS.
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